Αρχική World News Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with... World News Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL Από Ogkologos - 6 Αυγούστου, 2026 225 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BRUIN CLL-322 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Programme Highlights of the ESMO Virtual Congress 2020 [ESMO Media Alert] 28 Αυγούστου, 2020 An Increase in Healthcare Costs Associated with the Use of Multigene... 14 Φεβρουαρίου, 2024 Rediscovered Drugs Hit Leukemia from Two Different Angles 21 Ιουλίου, 2020 Lung Cancer Death Rates Among Women in Europe Are Finally Levelling... 19 Ιανουαρίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Foodie Friday: Pumpkin EVERYTHING! Sodium Thiosulfate Approved to Reduce Chemo-Related Hearing Loss in Children with... What is De-escalation Treatment in Cancer Research? FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma